The Companion Diagnostics Market size was estimated at USD 8.90 billion in 2025 and expected to reach USD 9.84 billion in 2026, at a CAGR of 10.99% to reach USD 18.48 billion by 2032.

Companion diagnostics (CDx) have become a central operating model for precision medicine, linking a validated diagnostic test to the safe and effective use of a specific therapy. In oncology, rare disease, infectious disease, and immunology, CDx enables clinicians to identify patients most likely to benefit from targeted treatment, avoid ineffective therapies, and support evidence-based reimbursement decisions.

Market momentum is reinforced by the rising global cancer burden, broader adoption of next-generation sequencing (NGS), increasing FDA-approved targeted therapies, and expanding use of biomarkers such as EGFR, ALK, BRAF, HER2, BRCA1/2, PD-L1, MSI, NTRK, and KRAS. As drug development becomes more biomarker-led, pharmaceutical companies, diagnostic developers, laboratories, and health systems are aligning around integrated clinical validation, regulatory strategy, and real-world evidence generation.

The companion diagnostics landscape is shifting from single-analyte testing toward multiplex and NGS-based platforms that can evaluate multiple actionable biomarkers from limited tissue or blood samples. This shift supports faster treatment selection, better use of biopsy material, and stronger alignment with modern oncology pathways where multiple targeted therapy options may be available for one tumor type.

Regulatory and reimbursement expectations are also transforming the sector. Agencies including the U.S. FDA require strong analytical and clinical validation for CDx claims, while payers increasingly assess clinical utility, guideline inclusion, and health-economic value. Liquid biopsy, decentralized testing networks, and tumor-agnostic biomarkers are further changing how precision medicine is delivered across community and academic care settings.

Artificial intelligence is influencing companion diagnostics by improving variant interpretation, digital pathology workflows, radiomics, laboratory automation, quality control, and clinical trial matching. AI-enabled tools can help prioritize genomic alterations, detect patterns in pathology images, and support evidence synthesis from real-world datasets when appropriately validated.

The cumulative impact of AI is expected to be strongest where it reduces turnaround time, improves reproducibility, and connects multi-omic data with therapy selection. However, adoption depends on transparent validation, representative training datasets, cybersecurity, explainability, and compliance with medical device regulations, HIPAA, GDPR, and emerging AI governance frameworks such as the European Union AI Act.

North America remains a leading region for companion diagnostics due to strong FDA regulatory pathways, a high concentration of biopharmaceutical innovators, broad molecular testing infrastructure, and rapid adoption of targeted oncology therapies. The United States anchors regional growth through extensive clinical trial activity, national guideline integration, and established laboratory-developed test and in vitro diagnostic ecosystems, while Canada benefits from public health technology assessment processes and expanding precision oncology programs.

Europe is shaped by the In Vitro Diagnostic Regulation, GDPR, national reimbursement systems, and strong translational research networks across Germany, France, Italy, Spain, and the United Kingdom. Asia-Pacific is expanding quickly as China, Japan, South Korea, India, Australia, and ASEAN countries invest in cancer genomics, domestic diagnostic manufacturing, and precision medicine access. Latin America is progressing through private-sector molecular diagnostics adoption and oncology modernization in Brazil and Mexico, while the Middle East and Africa are developing capabilities through tertiary care centers, national genomics initiatives, and growing demand for advanced cancer diagnostics.

The European Union is a pivotal group for companion diagnostics because IVDR has increased requirements for clinical evidence, performance evaluation, and notified body oversight, pushing manufacturers toward more rigorous data packages and stronger post-market surveillance. G7 markets provide mature reimbursement, academic research depth, and pharmaceutical pipelines that support early CDx integration into drug development, while NATO countries benefit from advanced healthcare infrastructure and cross-border research collaboration.

BRICS countries are increasingly important because of large patient populations, expanding oncology treatment access, and government support for genomics and local diagnostic capacity, particularly in China, India, and Brazil. ASEAN markets are gaining relevance as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines expand laboratory networks and oncology services, though reimbursement and infrastructure remain uneven. GCC countries are investing in precision medicine, genomic screening, and advanced cancer centers, positioning the region as a high-potential market for premium molecular diagnostics.

The United States leads in companion diagnostics commercialization through FDA-approved CDx pathways, strong oncology guidelines, high biopharma R&D spending, and widespread use of NGS panels. Canada emphasizes evidence-based adoption through provincial health systems, while Mexico and Brazil are expanding access through private oncology networks, reference laboratories, and growing demand for targeted therapies.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine advanced oncology care with national reimbursement decision-making and IVDR-aligned diagnostic standards, while Russia’s market is shaped by local healthcare funding and domestic diagnostic capacity. China is scaling precision oncology rapidly through local innovation and large clinical datasets, India is growing through cost-sensitive molecular testing and urban cancer centers, Japan and South Korea benefit from strong regulatory systems and advanced diagnostics companies, and Australia supports adoption through public reimbursement mechanisms and national cancer genomics initiatives.

Industry leaders should align CDx development with therapeutic development from the earliest clinical phases, ensuring biomarker strategy, assay design, sample logistics, and regulatory requirements are built into trial protocols. Co-development reduces approval risk and improves the probability that a diagnostic will be available when the therapy reaches the market.

Companies should prioritize scalable NGS and liquid biopsy platforms, invest in real-world evidence, and build reimbursement dossiers that demonstrate clinical utility and cost effectiveness. Strategic partnerships among pharmaceutical companies, diagnostic manufacturers, reference laboratories, hospitals, and digital health providers will be essential for faster turnaround time, equitable access, and broader precision medicine adoption.

This executive summary is developed using a secondary research framework that synthesizes publicly available information from regulatory agencies, clinical guidelines, peer-reviewed biomedical literature, company disclosures, health technology assessment bodies, and recognized public health organizations. Key sources typically include the U.S. FDA, European Commission, national health agencies, WHO, IARC, oncology guideline bodies, and scientific publications covering molecular diagnostics and targeted therapy.

The methodology emphasizes triangulation across regulatory approvals, biomarker-linked therapy trends, diagnostic platform adoption, regional healthcare infrastructure, reimbursement dynamics, and technology developments. Insights are validated against observable market signals such as CDx approvals, precision oncology programs, NGS utilization, AI governance developments, and expanding clinical use of tissue and liquid biopsy testing.

Companion diagnostics are no longer a specialized adjunct to drug development; they are a foundational component of precision medicine. As therapies become more biomarker-specific, the ability to deliver accurate, timely, and clinically validated diagnostic results will increasingly determine patient access, treatment outcomes, and commercial success.

The market outlook is supported by rising targeted therapy pipelines, expanding NGS adoption, liquid biopsy innovation, AI-enabled interpretation, and global investment in oncology infrastructure. Organizations that integrate regulatory excellence, evidence generation, reimbursement strategy, and laboratory scalability will be best positioned to lead the next phase of companion diagnostics growth.